GLP-1cagrisemacagrilintidesemaglutideobesitymeta-analysis

Meta-analysis finds CagriSema beats semaglutide 2.4 mg by 6.9 points

Pooling five trials and 4,746 participants, the combination roughly doubled the chance of 20% weight loss but tripled injection-site reactions.

By Maren Holt · Senior Reporter, GLP-1

Oct 1 20:00 ETSource: Frontiers in endocrinology

The wire

01Across five randomised trials, CagriSema produced 6.89 percentage points more weight loss than semaglutide 2.4 mg (95% CI -8.70 to -5.06), -7.16 kg absolute, and RR 2.10 for reaching 20% reduction.
02No incremental glycaemic benefit was detected; HbA1c and fasting glucose intervals fell within prespecified minimal important differences, while injection-site reactions rose (RR 3.14).
03Authors say evidence is insufficient to judge serious adverse events or neoplasms, and durability, cardiovascular outcomes and body composition remain undetermined.

From the source

CagriSema versus Semaglutide 2.4 mg monotherapy for weight management in adults with overweight or obesity, with or without type 2 diabetes: a systematic review, meta-analysis, and trial sequential analysis
Frontiers in endocrinology · 2026 · Rasool ZK, Shah R, Batool AEZ et al.

Read at pubmed.ncbi.nlm.nih.gov

Source URL https://pubmed.ncbi.nlm.nih.gov/42890523/